237 related articles for article (PubMed ID: 18568482)
1. Health-related quality of life during treatment for renal cell carcinoma: results from a phase II study of axitinib.
Trask PC; Bushmakin AG; Cappelleri JC; Bycott P; Liau K; Kim S
Acta Oncol; 2008; 47(5):843-51. PubMed ID: 18568482
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma.
Rini BI; Wilding G; Hudes G; Stadler WM; Kim S; Tarazi J; Rosbrook B; Trask PC; Wood L; Dutcher JP
J Clin Oncol; 2009 Sep; 27(27):4462-8. PubMed ID: 19652060
[TBL] [Abstract][Full Text] [Related]
3. Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma.
Tomita Y; Uemura H; Fujimoto H; Kanayama HO; Shinohara N; Nakazawa H; Imai K; Umeyama Y; Ozono S; Naito S; Akaza H;
Eur J Cancer; 2011 Nov; 47(17):2592-602. PubMed ID: 21889330
[TBL] [Abstract][Full Text] [Related]
4. Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma.
Fruehauf J; Lutzky J; McDermott D; Brown CK; Meric JB; Rosbrook B; Shalinsky DR; Liau KF; Niethammer AG; Kim S; Rixe O
Clin Cancer Res; 2011 Dec; 17(23):7462-9. PubMed ID: 21976544
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study.
Schiller JH; Larson T; Ou SH; Limentani S; Sandler A; Vokes E; Kim S; Liau K; Bycott P; Olszanski AJ; von Pawel J
J Clin Oncol; 2009 Aug; 27(23):3836-41. PubMed ID: 19597027
[TBL] [Abstract][Full Text] [Related]
6. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.
Hutson TE; Lesovoy V; Al-Shukri S; Stus VP; Lipatov ON; Bair AH; Rosbrook B; Chen C; Kim S; Vogelzang NJ
Lancet Oncol; 2013 Dec; 14(13):1287-94. PubMed ID: 24206640
[TBL] [Abstract][Full Text] [Related]
7. Does axitinib (AG-01376) have a future role in metastatic renal cell carcinoma and other malignancies?
Goldstein R; Pickering L; Larkin J
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1545-57. PubMed ID: 20942625
[TBL] [Abstract][Full Text] [Related]
8. Lenalidomide therapy for metastatic renal cell carcinoma.
Amato RJ; Hernandez-McClain J; Saxena S; Khan M
Am J Clin Oncol; 2008 Jun; 31(3):244-9. PubMed ID: 18525302
[TBL] [Abstract][Full Text] [Related]
9. Response assessment classification in patients with advanced renal cell carcinoma treated on clinical trials.
Schwartz LH; Mazumdar M; Wang L; Smith A; Marion S; Panicek DM; Motzer RJ
Cancer; 2003 Oct; 98(8):1611-9. PubMed ID: 14534876
[TBL] [Abstract][Full Text] [Related]
10. Feasibly of axitinib as first-line therapy for advanced or metastatic renal cell carcinoma: a single-institution experience in Japan.
Koie T; Ohyama C; Yoneyama T; Yamamoto H; Imai A; Hatakeyama S; Hashimoto Y; Yoneyama T; Tobisawa Y; Mori K
BMC Urol; 2015 Apr; 15():32. PubMed ID: 25887125
[TBL] [Abstract][Full Text] [Related]
11. An early phase II trial of S-1 in Japanese patients with cytokine-refractory metastatic renal cell carcinoma.
Naito S; Tsukamoto T; Usami M; Fujimoto H; Akaza H
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1065-70. PubMed ID: 20157711
[TBL] [Abstract][Full Text] [Related]
12. Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma.
Akaza H; Tsukamoto T; Murai M; Nakajima K; Naito S
Jpn J Clin Oncol; 2007 Oct; 37(10):755-62. PubMed ID: 17951335
[TBL] [Abstract][Full Text] [Related]
13. Axitinib in the treatment of metastatic renal cell carcinoma.
Ho TH; Jonasch E
Future Oncol; 2011 Nov; 7(11):1247-53. PubMed ID: 22044199
[TBL] [Abstract][Full Text] [Related]
14. Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: a randomized phase III clinical trial.
Ravaud A; Hawkins R; Gardner JP; von der Maase H; Zantl N; Harper P; Rolland F; Audhuy B; Machiels JP; Pétavy F; Gore M; Schöffski P; El-Hariry I
J Clin Oncol; 2008 May; 26(14):2285-91. PubMed ID: 18467719
[TBL] [Abstract][Full Text] [Related]
15. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study.
Rixe O; Bukowski RM; Michaelson MD; Wilding G; Hudes GR; Bolte O; Motzer RJ; Bycott P; Liau KF; Freddo J; Trask PC; Kim S; Rini BI
Lancet Oncol; 2007 Nov; 8(11):975-84. PubMed ID: 17959415
[TBL] [Abstract][Full Text] [Related]
16. Axitinib safety in metastatic renal cell carcinoma: suggestions for daily clinical practice based on case studies.
Bracarda S; Castellano D; Procopio G; Sepúlveda JM; Sisani M; Verzoni E; Schmidinger M
Expert Opin Drug Saf; 2014 Apr; 13(4):497-510. PubMed ID: 24641566
[TBL] [Abstract][Full Text] [Related]
17. Health-related quality of life in patients treated for anaplastic oligodendroglioma with adjuvant chemotherapy: results of a European Organisation for Research and Treatment of Cancer randomized clinical trial.
Taphoorn MJ; van den Bent MJ; Mauer ME; Coens C; Delattre JY; Brandes AA; Sillevis Smitt PA; Bernsen HJ; Frénay M; Tijssen CC; Lacombe D; Allgeier A; Bottomley A;
J Clin Oncol; 2007 Dec; 25(36):5723-30. PubMed ID: 18089866
[TBL] [Abstract][Full Text] [Related]
18. Lonidamine versus high-dose tamoxifen in progressive, advanced renal cell carcinoma: results of an ongoing randomized phase II study.
Stahl M; Schmoll E; Becker H; Schlichter A; Hoffmann L; Wagner H; Possinger K; Müller W; Köllermann M; Weidenhammer W
Semin Oncol; 1991 Apr; 18(2 Suppl 4):33-7. PubMed ID: 2031196
[TBL] [Abstract][Full Text] [Related]
19. Axitinib for the treatment of advanced renal cell carcinoma.
Akaza H; Fukuyama T
Expert Opin Pharmacother; 2014 Feb; 15(2):283-97. PubMed ID: 24328549
[TBL] [Abstract][Full Text] [Related]
20. Five-year survival in patients with cytokine-refractory metastatic renal cell carcinoma treated with axitinib.
Rini BI; de La Motte Rouge T; Harzstark AL; Michaelson MD; Liu G; Grünwald V; Ingrosso A; Tortorici MA; Bycott P; Kim S; Bloom J; Motzer RJ
Clin Genitourin Cancer; 2013 Jun; 11(2):107-14. PubMed ID: 23391371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
